Dai, Guanghai

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)	Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)	Not yet recruiting	Phase 2	2026-09-01	NCT07797244
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer	Gastric Cancer Adenocarcinoma Metastatic	Recruiting	Phase 2	2026-02-11	NCT07392346
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV	Advanced Pancreatic Cancer (Part 1)	Recruiting	Phase 1 / Phase 2	2025-01-20	NCT06782685
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer	Advanced Biliary Tract Cancer	Recruiting	Phase 2	2024-11-27	NCT06708858
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer	Colorectal Cancer Metastatic	Recruiting	Phase 2	2024-11-20	NCT06685276

Clinical trials